Glonghui, December 26|Dongfulong (300171.SZ) Investor Interactive Platform stated that the company's bioprocess sector business mainly provides customers with various equipment, instruments, and consumables that meet the needs of customers in application scenarios such as chemical raw materials for small molecule drugs, raw materials extracted from traditional Chinese medicine, biological stock solutions for macromolecule drugs, and preparation of cell-gene therapy drugs. The company's products have already been used in the field of synthetic biology.
东富龙(300171.SZ)：公司产品已经在客户合成生物学领域业务中有所应用
Tofulong (300171.SZ): The company's products have been used in the customer's synthetic biology business
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.